We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · September 06, 2022

Intravesical Pembrolizumab Induces Immune Activation in BCG-Unresponsive Bladder Cancer

European Urology


Additional Info

European Urology
First-in-human Intravesical Delivery of Pembrolizumab Identifies Immune Activation in Bladder Cancer Unresponsive to Bacillus Calmette-Guérin
Eur Urol 2022 Aug 22;[EPub Ahead of Print], K Meghani, LF Cooley, B Choy, M Kocherginsky, S Swaminathan, SS Munir, RS Svatek, T Kuzel, JJ Meeks

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading